Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | ATM serine/threonine kinase | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trypanosoma brucei | phosphatidylinositol kinase related protein, putative | 0.003 | 0.5475 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trypanosoma brucei | phosphatidylinositol 4-kinase, putative | 0.0022 | 0.273 | 0.4987 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 1 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Brugia malayi | Phosphatidylinositol 3- and 4-kinase family protein | 0.003 | 0.5475 | 0.3776 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trypanosoma cruzi | phosphatidylinositol kinase related protein, putative | 0.0022 | 0.2745 | 0.0052 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Echinococcus multilocularis | serine protein kinase ATM | 0.003 | 0.5475 | 0.3776 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 1 | 1 |
Leishmania major | phosphatidylinositol kinase related protein, putative | 0.0022 | 0.2745 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Loa Loa (eye worm) | phosphatidylinositol 3 | 0.0022 | 0.273 | 0.6723 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.003 | 0.5475 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Trypanosoma brucei | Phosphatidylinositol 3-kinase tor1 | 0.0022 | 0.273 | 0.4987 |
Schistosoma mansoni | ataxia telangiectasia mutated (atm) | 0.003 | 0.5475 | 0.3776 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 1 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Toxoplasma gondii | FATC domain-containing protein | 0.003 | 0.5475 | 1 |
Echinococcus granulosus | serine protein kinase ATM | 0.003 | 0.5475 | 0.3776 |
Trypanosoma brucei | phosphatidylinositol 3-related kinase, putative | 0.0022 | 0.273 | 0.4987 |
Giardia lamblia | GTOR | 0.0022 | 0.273 | 0.5 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Trypanosoma cruzi | phosphatidylinositol kinase related protein, putative | 0.003 | 0.5475 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trypanosoma cruzi | phosphatidylinositol kinase related protein, putative | 0.0026 | 0.4061 | 0.4849 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 1 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.4061 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Entamoeba histolytica | hypothetical protein | 0.003 | 0.5475 | 0.3776 |
Toxoplasma gondii | target of rapamycin (TOR), putative | 0.0022 | 0.273 | 0.4987 |
Loa Loa (eye worm) | phosphatidylinositol 3 | 0.0022 | 0.273 | 0.6723 |
Trypanosoma brucei | phosphatidylinositol 3-kinase, putative | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Trypanosoma brucei | target of rapamycin kinase 3, putative | 0.0022 | 0.273 | 0.4987 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0022 | 0.273 | 0.4987 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.5221 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.8048 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (binding) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.